Narendra Chirmule
Biocon Ltd., India
Posters & Accepted Abstracts: J Antivir Antiretrovir
The advent of preventive vaccines in the past decade has had a major impact on the incidence of cervical cancer worldwide. The immune responses involved in developing protection involve neutralizing antibody formation which persists. The advances in development of therapeutics treatment of cervical cancer have been limited. In India, the estimates of approximately 132,000 new cases diagnosed and 74,000 deaths annually in India, accounting to nearly 1/3rd of the global cervical cancer deaths is staggering. There is a dire need to develop therapies to address this major health concern. The HPV-2016 international conference provides a forum to discuss the challenges for managing prevention and treatment of cervical cancer. This presentation will review the cervical cancer in India and the advances in novel therapeutics including immunotherapies in the treatment of this disease.
Email: narendra.chirmule@biocon.com
